ATA75295A - Rekombinante poxviren mit fremd-dna in essentiellen regionen - Google Patents

Rekombinante poxviren mit fremd-dna in essentiellen regionen

Info

Publication number
ATA75295A
ATA75295A AT0075295A AT75295A ATA75295A AT A75295 A ATA75295 A AT A75295A AT 0075295 A AT0075295 A AT 0075295A AT 75295 A AT75295 A AT 75295A AT A75295 A ATA75295 A AT A75295A
Authority
AT
Austria
Prior art keywords
foreign dna
defective
poxvirus
essential regions
recombinant poxviruses
Prior art date
Application number
AT0075295A
Other languages
English (en)
Other versions
AT405292B (de
Inventor
Falko-Guenter Dr Falkner
Georg Dipl Ing Holzer
Friedrich Dr Dorner
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22885307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATA75295(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of ATA75295A publication Critical patent/ATA75295A/de
Application granted granted Critical
Publication of AT405292B publication Critical patent/AT405292B/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/55—Vector systems having a special element relevant for transcription from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT0075295A 1994-04-29 1995-05-02 Rekombinante poxviren mit fremd-dna in essentiellen regionen AT405292B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23539294A 1994-04-29 1994-04-29

Publications (2)

Publication Number Publication Date
ATA75295A true ATA75295A (de) 1998-11-15
AT405292B AT405292B (de) 1999-06-25

Family

ID=22885307

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95919361T ATE298370T1 (de) 1994-04-29 1995-04-28 Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
AT0075295A AT405292B (de) 1994-04-29 1995-05-02 Rekombinante poxviren mit fremd-dna in essentiellen regionen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95919361T ATE298370T1 (de) 1994-04-29 1995-04-28 Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen

Country Status (10)

Country Link
US (2) US5766882A (de)
EP (1) EP0758397B1 (de)
JP (1) JP3911010B2 (de)
AT (2) ATE298370T1 (de)
AU (1) AU694519B2 (de)
CA (1) CA2188447C (de)
DE (1) DE69534289T2 (de)
DK (1) DK0758397T3 (de)
ES (1) ES2243937T3 (de)
WO (1) WO1995030018A2 (de)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7374768B1 (en) * 1990-09-25 2008-05-20 Xenova Research Limited Viral vaccines
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
IL125797A0 (en) * 1996-02-28 1999-04-11 Bayer Ag Parapoxviruses which contain foreign dna their preparation and their use in vaccines
US6428965B1 (en) * 1997-07-17 2002-08-06 The Johns Hopkins University Screening assays for the interaction of semaphorins and neuropilins
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
AT406376B (de) 1998-01-16 2000-04-25 Immuno Ag Chimäres poxvirus enthaltend eine retrovirale vektorkomponente
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
WO2002102855A2 (en) * 2000-11-17 2002-12-27 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US20050196755A1 (en) * 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US7628980B2 (en) * 2000-11-23 2009-12-08 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
CZ295808B6 (cs) 2000-11-23 2005-11-16 Bavarian Nordic A/S Modifikovaný virus vakcinie typu Ankara
US7097842B2 (en) * 2000-11-23 2006-08-29 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
US20030104402A1 (en) * 2001-01-23 2003-06-05 University Of Rochester Methods of producing or identifying intrabodies in eukaryotic cells
AU2002255495A1 (en) * 2001-02-02 2002-08-19 University Of Rochester Methods of identifying regulator molecules
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
PT1504108E (pt) 2002-02-01 2013-06-12 Oxford Biomedica Ltd Vetor lentiviral
KR101028937B1 (ko) * 2002-04-19 2011-04-12 버베리안 노딕 에이/에스 신생아의 백신접종용 변형 백시니아 바이러스 안카라
NZ538575A (en) * 2002-09-05 2007-03-30 Bavarian Nordic As Method for the amplification of a virus wherein primary avian cells are cultivated in a serum-free medium comprising growth factors and attachment factors
WO2005019449A2 (en) * 2003-07-03 2005-03-03 Board Of Trustees Operating Michigan State University Expression of a recombinant transgene
WO2005028634A2 (en) * 2003-09-18 2005-03-31 Emory University Improved mva vaccines
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
US20080053516A1 (en) * 2006-08-30 2008-03-06 Richard Allen Hayes Solar cell modules comprising poly(allyl amine) and poly (vinyl amine)-primed polyester films
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
DK3360571T3 (da) 2007-05-03 2021-01-04 Agency For Science Tech And Research Astarstar Antistoffer, der binder til et intracellulært PRL-1- eller PRL-3-polypeptid
WO2010071610A1 (en) 2008-12-19 2010-06-24 Agency For Science, Technology And Research (A*Star) Severe chikungunya biomarkers
CN102573452B (zh) 2009-08-19 2015-07-22 陶氏益农公司 Aad-1事件das-40278-9、相关的转基因玉米品系及其事件特异性鉴定
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
GB201006405D0 (en) 2010-04-16 2010-06-02 Isis Innovation Poxvirus expression system
EP2618840A2 (de) 2010-09-23 2013-07-31 Baxter International Inc. Rekombinante virusvektoren und verfahren zur auslösung einer immunreaktion auf gelbfiebervirus
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
US20130171189A1 (en) * 2011-10-14 2013-07-04 University Of Connecticut Inducible and repressible vaccinia viruses with improved safety
US9708601B2 (en) 2012-04-26 2017-07-18 Vaccinex, Inc. Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus
WO2014127825A1 (en) 2013-02-21 2014-08-28 Boehringer Ingelheim Vetmedica Gmbh H5 proteins of h5n1 influenza virus for use as a medicament
MX2016003855A (es) 2013-09-25 2016-08-04 Zoetis Services Llc Composicion de vacuna de circovirus porcino tipo 2b divergente y procedimientos de uso.
CA2931518C (en) * 2013-11-01 2021-03-09 Sementis Limited Viral vector manufacture
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
GB201322574D0 (en) 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
EP3125932A1 (de) 2014-04-03 2017-02-08 Boehringer Ingelheim Vetmedica, Inc. Impfstoff gegen porzine epidemische virusdiarrhoe
US10894966B2 (en) 2014-09-26 2021-01-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus-based expression vectors and uses thereof
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (de) 2014-12-19 2020-11-25 The Broad Institute, Inc. Verfahren zum profiling vom t-zell-rezeptor-repertoire
CN107735103B (zh) 2015-02-25 2022-05-27 纪念斯隆-凯特琳癌症中心 使用灭活的非复制型的修饰的痘苗病毒安卡拉(mva)作为实体肿瘤的单一免疫疗法或与免疫检查点阻断剂的组合
CA2982896A1 (en) 2015-04-17 2016-10-20 Memorial Sloan Kettering Cancer Center Use of modified vaccinia ankara virus (mva) or mva with a deletion of virulence factor e8 as immunotherapeutic agent against solid tumors
AU2016264623B2 (en) 2015-05-20 2022-06-30 Dana-Farber Cancer Institute, Inc. Shared neoantigens
TWI750122B (zh) 2015-06-09 2021-12-21 美商博德研究所有限公司 用於贅瘤疫苗之調配物及其製備方法
DE102015111756A1 (de) * 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
EA036116B1 (ru) 2015-08-31 2020-09-30 Берингер Ингельхайм Ветмедика Гмбх Пестивирусные вакцины против врожденного тремора
WO2017048677A1 (en) 2015-09-16 2017-03-23 Boehringer Ingelheim Vetmedica, Inc. Salmonella choleraesuis-salmonella typhimurium vaccines
CN109152827B (zh) 2016-02-25 2023-07-21 纪念斯隆凯特琳癌症中心 重组mva或表达人flt3l的mvaδe3l及其作为抗固体肿瘤的免疫治疗剂的用途
KR20180133395A (ko) 2016-02-25 2018-12-14 메모리얼 슬로안 케터링 캔서 센터 암 면역요법을 위한, 인간 flt3l 또는 gm-csf의 발현이 있거나 없으며 티미딘 키나제가 결실된 복제 가능 약독화 백시니아 바이러스
AU2017254477A1 (en) 2016-04-18 2018-11-01 Jennifer G. ABELIN Improved HLA epitope prediction
EP3494131A4 (de) 2016-08-02 2020-04-15 Vaccinex, Inc. Verbesserte verfahren zur herstellung von polynukleotidbibliotheken in vaccinia virus/eukaryotischen zellen
KR20190050787A (ko) * 2016-08-19 2019-05-13 세멘티스 리미티드 바이러스 백신
EP3516064A1 (de) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH Neue promotoren
EP3515504B1 (de) 2016-09-20 2023-07-12 Boehringer Ingelheim Vetmedica GmbH Hundeadenovirus vektor
US10619169B2 (en) 2016-09-20 2020-04-14 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site ORF70
MX2019003116A (es) 2016-09-20 2019-08-29 Boehringer Ingelheim Vetmedica Gmbh Nueva vacuna contra la gripe porcina.
UA127859C2 (uk) 2016-11-03 2024-01-31 Бьорінгер Інгельхайм Ветмедіка Гмбх Вакцина проти свинячого парвовірусу
PT3534939T (pt) 2016-11-03 2023-04-20 Boehringer Ingelheim Vetmedica Gmbh Vacina contra parvovírus porcino e vírus da síndrome reprodutiva e respiratória porcina e métodos da sua produção
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP2020506915A (ja) 2017-01-30 2020-03-05 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド ブタコロナウイルスワクチン
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
WO2019014144A1 (en) 2017-07-12 2019-01-17 Boehringer Ingelheim Vetmedica, Inc. IMMUNOGENIC COMPOSITIONS BASED ON SENECAVIRUS TYPE A AND CORRESPONDING METHODS
BR112020005767A2 (pt) 2017-09-23 2020-10-13 Boehringer Ingelheim Vetmedica Gmbh sistema de expressão de paramyxoviridae
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
BR112020017239A2 (pt) 2018-02-23 2020-12-22 Boehringer Ingelheim Vetmedica Gmbh Sistemas de vetor viral recombinante que expressam genes de paramixovírus felino exógenos e vacinas feitas a partir deles
WO2019179998A1 (en) 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh New ehv with inactivated ul18 and/or ul8
CA3091960A1 (en) 2018-03-19 2019-09-26 Boehringer Ingelheim Vetmedica Gmbh New ehv insertion site ul43
WO2019191005A1 (en) 2018-03-26 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
EP3852800A1 (de) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasaler vektorimpfstoff gegen epidemische virusdiarrhoe
TW202027785A (zh) 2018-09-20 2020-08-01 德商百靈佳殷格翰維美迪加股份有限公司 經修飾之pedv棘蛋白
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
US11858962B2 (en) 2020-02-06 2024-01-02 Boehringer Ingelheim Vetmedica Gmbh Polypeptides useful for detecting anti-rhabdovirus antibodies
WO2021242793A2 (en) 2020-05-26 2021-12-02 The Broad Institute, Inc. Nucleic acid artificial mini-proteome libraries
JP2023544403A (ja) 2020-10-05 2023-10-23 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド サーコウイルス科カプシドタンパク質を含む融合タンパク質、及びそれから構成されるキメラウイルス様粒子
BR112023006274A2 (pt) 2020-10-05 2023-05-09 Boehringer Ingelheim Vetmedica Gmbh Proteína de fusão útil para vacinação contra rotavírus
WO2023076733A1 (en) 2021-11-01 2023-05-04 Dana-Farber Cancer Institute, Inc. Biologically selected nucleic acid artificial mini-proteome libraries
GB202117405D0 (en) 2021-12-02 2022-01-19 Univ London Queen Mary Peptide
WO2023194913A1 (en) 2022-04-05 2023-10-12 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus
WO2024015892A1 (en) 2022-07-13 2024-01-18 The Broad Institute, Inc. Hla-ii immunopeptidome methods and systems for antigen discovery

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) * 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) * 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5338683A (en) * 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US5505941A (en) * 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5155020A (en) * 1989-03-08 1992-10-13 Health Research Inc. Recombinant poxvirus host range selection system
US4722848A (en) * 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5225336A (en) * 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
CH682669A5 (fr) * 1989-03-08 1993-10-29 Health Research Inc Virus recombinant modifié pour exprimer un produit de gènes chez un hôte, procédés et vaccin correspondants.
GB8907468D0 (en) * 1989-04-03 1989-05-17 Smith Geoffrey L Vaccinia vectors,vaccinia genes and expression products thereof
AU634773B2 (en) * 1989-05-08 1993-03-04 Basil Arif Spheroidin dna isolate and recombinant entomopoxvirus expression vectors
US5204243A (en) * 1990-02-14 1993-04-20 Health Research Incorporated Recombinant poxvirus internal cores
JP3895366B2 (ja) * 1990-09-25 2007-03-22 キャンタブ ファーマシューティカルズ リサーチ リミティド ウィルス ワクチン
GB9023352D0 (en) * 1990-10-26 1990-12-05 Lynxvale Ltd Vaccinia vectors,vaccinia genes and expression products thereof
US5863542A (en) * 1991-03-07 1999-01-26 Virogenetics Corporation Recombinant attenuated ALVAC canaryopox virus containing heterologous HIV or SIV inserts
US5997878A (en) * 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
US5989561A (en) * 1991-03-07 1999-11-23 Virogenetics Corporation Recombinant poxvirus-calicivirus rabbit hemorrhagic disease virus (RHDV) compositions and uses
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5843456A (en) * 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
DK0538496T3 (da) * 1991-08-26 2004-02-23 Baxter Healthcare Sa Rekombinant fjerkrækoppevirus med intakt FPV tk-gen
WO1996021727A1 (en) * 1995-01-13 1996-07-18 Virogenetics Corporation Immunogenic compositions containing recombinant attenuated poxviruses expressing htlv antigens
WO1994003595A1 (en) * 1992-07-30 1994-02-17 Akzo Nobel N.V. Non-shedding live herpesvirus vaccine

Also Published As

Publication number Publication date
DK0758397T3 (da) 2005-10-10
AT405292B (de) 1999-06-25
US5766882A (en) 1998-06-16
ES2243937T3 (es) 2005-12-01
EP0758397A1 (de) 1997-02-19
AU694519B2 (en) 1998-07-23
US5770212A (en) 1998-06-23
EP0758397B1 (de) 2005-06-22
JPH09512707A (ja) 1997-12-22
DE69534289D1 (de) 2005-07-28
WO1995030018A3 (en) 1996-01-04
CA2188447C (en) 2002-10-22
AU2523095A (en) 1995-11-29
JP3911010B2 (ja) 2007-05-09
WO1995030018A2 (en) 1995-11-09
ATE298370T1 (de) 2005-07-15
DE69534289T2 (de) 2006-04-27
CA2188447A1 (en) 1995-11-09

Similar Documents

Publication Publication Date Title
ATA75295A (de) Rekombinante poxviren mit fremd-dna in essentiellen regionen
MX164250B (es) Metodo mejorado para producir un vector de expresion de baculovirus recombinante
NL300257I2 (nl) Transgene dieren die gewenste eiwitten in de melk afscheiden.
DE3853088D1 (de) Rekombinantes Avipoxvirus.
DE69734930D1 (de) Adenovirales fiberprotein mit einem kurzen schaft und seine verwendung
DE3850019T2 (de) Rekombinantes Avipoxvirus.
DE68927511D1 (de) DNS-Sequenzen, die Polypeptiden mit beta-1,3-Glukanase-Aktivität codieren
ES2163864T3 (es) Secuencias de dna de 2-desoxiglucosa-6-fosfato (2-dog-6-p) como marcador de seleccion en plantas.
DE69031389D1 (de) Schnelle, vielseitige und einfache methode zur expression von genen in eukaryotischen zellen
ATE232237T1 (de) Herstellung von funktionellen, menschlichen urokinaseproteinen
HU9201746D0 (en) Recombinant avipox virus, the virus infected cell cultivation and the vaccine resulted from it for poultry vaccination
ATE252153T1 (de) Rekombinanter birnavirusimpfstoff
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
EP0256677A3 (de) Pseudorabiesvirus-Rekombinanten und ihre Verwendung zur Herstellung von Proteinen
ATE286509T1 (de) Interferon alpha/beta bindendes protein, seine herstellung und anwendung
FI963755A (fi) Glutamaatti-dekarboksylaasi-aktiivisuutta (GAD-aktiivisuutta) koodaavat yhdistelmä-DNA-tekniset virukset
NO864742D0 (no) Dna-sekvens som koder for human vevsplasminogenaktivator, rekombinant dna-sekvens, vertcelle transformert med denne samt fremgangsmaate for fremstilling av plasminogenaktivatoren.
DE3856199D1 (de) Impfstoff gegen cholera
Tasaka et al. Enzymatic Studies on the Egg white Proteins On the Variation of pH and Denaturation of Protein during the Course of storage (Part 2)
ATE84315T1 (de) Rekombinante dna zur reprimierbaren und induzierbaren expression von fremdgenen.
DK638789D0 (da) Alfa2-plasmininhibitoranalog, dna og rekombinant-dna2-fragment, som koder derfor, samt plasmid, vaertsceller og fremgangsmaade til dens fremstilling
IT8020737V0 (it) Suola in gomma per scarponi, provvista di chiodi conici arrotondati ed opportunamente distanziati.

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee
ELJ Ceased due to non-payment of the annual fee